Liquidia Corporation
Inhaled/dry-powder cardiopulmonary therapeutics (PRINT technology)
LQDA · Nasdaq · United States
Share price · LQDA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when LQDA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 14 Oct 2026+26.6%
- 30 Sep 2026-57.2%
- 28 Sep 2026+7.7%
Nothing announced by LQDA that day or the session before.
- 13 Aug 2026-8.5%
- 12 Aug 2026-10.5%
- 4 Jun 2026+12.3%
Nothing announced by LQDA that day or the session before.
- 11 May 2026+25.6%
- 25 Feb 2026-10.6%
Nothing announced by LQDA that day or the session before.
- 17 Feb 2026-11.4%
Nothing announced by LQDA that day or the session before.
- 9 Jan 2026+12.9%
Share of unusual movement by asset
For each asset, the share of LQDA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | IP receptor (prostacyclin pathway)Small molecule | Pulmonary Arterial HypertensionPulmonary Hypertension Associated with Interstitial Lung DiseaseSystemic Sclerosis | |
| Phase 3 | IP receptor (prostacyclin pathway)Small molecule | Pulmonary Arterial HypertensionPulmonary Hypertension Associated with Interstitial Lung Disease |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (18)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $225M | $25M | $396M | $236M$147M operating cash flow | report ↗ |
View 17 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $172M | $17M | $284M | —$80M operating cash flow | report ↗ |
| 2026-Q1 | $133M | $13M | $223M | —$53M operating cash flow | report ↗ |
| 2025-Q3 | $54M | $9.3M | $158M | $3.5M-$9.8M operating cash flow | report ↗ |
| 2025-Q2 | $8.8M | $6.0M | $173M | $42M-$39M operating cash flow | report ↗ |
| 2025-Q1 | $3.1M | $7.0M | $170M | $38M-$31M operating cash flow | report ↗ |
| 2024-Q4 | $2.9M | — | $176M | $39M-$21M operating cash flow | report ↗ |
| 2024-Q3 | $4.5M | $12M | $204M | $23M-$25M operating cash flow | report ↗ |
| 2024-Q2 | $3.7M | $9.4M | $133M | $28M-$23M operating cash flow | report ↗ |
| 2024-Q1 | $3.0M | $10M | $158M | $41M-$25M operating cash flow | report ↗ |
| 2023-Q4 | $4.5M | — | $84M | $27M-$16M operating cash flow | report ↗ |
| 2023-Q3 | $3.7M | $7.4M | $76M | $16M-$12M operating cash flow | report ↗ |
| 2023-Q2 | $4.8M | $18M | $88M | $24M-$5.6M operating cash flow | report ↗ |
| 2023-Q1 | $4.5M | $5.3M | $94M | $12M-$8.5M operating cash flow | report ↗ |
| 2022-Q3 | $3.2M | $4.5M | $98M | $9.1M-$5.8M operating cash flow | report ↗ |
| 2022-Q2 | $3.9M | $5.2M | $104M | $9.4M-$8.4M operating cash flow | report ↗ |
| 2022-Q1 | $3.5M | $4.7M | $58M | $16M-$9.8M operating cash flow | report ↗ |
| 2021-Q3 | $3.2M | $4.5M | $64M | $7.3M-$5.8M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $158M | $39M | $191M | $17M-$36M operating cash flow | report ↗ |
For full-year 2025, Liquidia reported total revenue of $158.32M, up 1030.9% YoY, driven by YUTREPIA net product sales of $148.3M and service revenue of $10.0M. R&D expenses were $39.28M, down 17.9% YoY, and cash and cash equivalents stood at $190.68M at year-end. The company reported a full-year net loss of $68.92M, while fourth-quarter 2025 net income was $14.6M with positive non-GAAP adjusted EBITDA of $27.3M.
Following YUTREPIA’s FDA approval in May 2025 and US launch in June 2025, the company had received more than 3,600 unique prescriptions and started over 2,900 patients on treatment, with approximately 860 prescribers. Management said it plans to deepen prescriber adoption, grow the sales force, expand YUTREPIA’s clinical evidence through additional studies, and advance L606 into pivotal trials, all intended to be funded from operations. L606 is being evaluated in an open-label US study for PAH and PH-ILD and in a global pivotal placebo-controlled study for PH-ILD; the company also noted ongoing YUTREPIA-related litigation that could affect continued commercialization.
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($318K), 170 sales ($227.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-16 | Alterson Harold · See Remarks | Award / grant | 5,322 | — | — | Form 4 |
| 2026-11-16 | KIRSCH ARTHUR S · director | Option exercise | 8,914 | $20.36 | $181K | Form 4 |
| 2026-11-16 | Schundler Russell · See Remarks | Award / grant | 8,870 | — | — | Form 4 |
| 2026-11-16 | KIRSCH ARTHUR S · director | Option exercise (derivative) | 8,914 | — | — | Form 4 |
| 2026-10-26 | Adair Jason · Chief Business Officer | Open-market sale | 688 | $43.19 | $30K | Form 4 |
| 2026-10-26 | Boyle Dana · Chief Accounting Officer | Open-market sale | 1,581 | $43.19 | $68K | Form 4 |
| 2026-10-12 | Khindri Sanjeev · Chief Development Officer | Open-market sale | 1,101 | $28.48 | $31K | Form 4 |
| 2026-10-12 | Boyle Dana · Chief Accounting Officer | Open-market sale | 5,892 | $28.48 | $168K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 242 reporting institutions held 61.6M shares ($2.3B, 68.3% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FARALLON CAPITAL MANAGEMENT LLC | 8,656,038 | $326.7M |
| 2 | Caligan Partners LP | 8,118,892 | $306.4M |
| 3 | BlackRock, Inc. | 5,489,144 | $207.2M |
| 4 | FINDELL CAPITAL MANAGEMENT LLC | 3,502,112 | $132.2M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 2,926,945 | $110.5M |
| 6 | Opaleye Management Inc. | 2,545,000 | $88.8M |
| 7 | BANK OF AMERICA CORP /DE/ | 2,287,792 | $86.3M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1,928,969 | $72.8M |
| 9 | STATE STREET CORP | 1,881,599 | $71.0M |
| 10 | MPM BIOIMPACT LLC | 1,405,158 | $53.0M |
| 11 | Caprock Group, LLC | 1,367,235 | $51.6M |
| 12 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,001,081 | $37.8M |
| 13 | D. E. Shaw & Co., Inc. | 873,065 | $32.9M |
| 14 | GOLDMAN SACHS GROUP INC | 811,990 | $30.6M |
| 15 | JANE STREET GROUP, LLC | 795,884 | $30.0M |